Drug intelligence / Profile preview

UA026

Development stage: Phase 1
Lead developer: Usynova Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

UA026 is an investigational oral medication currently being evaluated in clinical trials for the treatment of moderate to severe plaque psoriasis. It is studied in a randomized, double-blind, placebo-controlled setting to assess its safety, tolerability, pharmacokinetic profile, and food effect in both healthy adults and adult subjects with moderate to severe plaque psoriasis. The precise mechanism of action and molecular target of UA026 have not been disclosed in public domain clinical trial records as of July 2025[3][5][7].

Other names: UA026UA-026UA 026

Beyond the preview

Go deeper on UA026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UA026.

Explore the full profile